

David J Brayden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6597857/publications.pdf>

Version: 2024-02-01

161
papers

7,352
citations

57681

46
h-index

73587

79
g-index

167
all docs

167
docs citations

167
times ranked

8724
citing authors

#	ARTICLE	IF	CITATIONS
1	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	1.9	29
2	Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. <i>Acta Biomaterialia</i> , 2022, 140, 561-572.	4.1	13
3	Add Sugar to Chitosan: Mucoadhesion and In Vitro Intestinal Permeability of Mannosylated Chitosan Nanocarriers. <i>Pharmaceutics</i> , 2022, 14, 830.	2.0	6
4	A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development. <i>AAPS Journal</i> , 2022, 24, 61.	2.2	2
5	Per Artursson's Major Contributions to the Caco-2 Cell Literature in Pharmaceutical Sciences. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 12-16.	1.6	1
6	Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 235-254.	2.5	8
7	Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 273-300.	2.4	36
8	Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): Isolated rat intestinal mucosae and sacs. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105685.	1.9	22
9	Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: in vitro and ex vivo intestinal and buccal bioassays. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105737.	1.9	16
10	Protein kinase D, ubiquitin and proteasome pathways are involved in adenosine receptor-stimulated NR4A expression in myeloid cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 19-25.	1.0	2
11	Permeability-enhancing effects of three laurate-disaccharide monoesters across isolated rat intestinal mucosae. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120593.	2.6	7
12	Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System. <i>Pharmaceutics</i> , 2021, 13, 656.	2.0	4
13	Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1501-1512.	2.4	39
14	Entrapment of Hydrophilic and Hydrophobic Molecules in Beads Prepared from Isolated Denatured Whey Protein. <i>Pharmaceutics</i> , 2021, 13, 1001.	2.0	1
15	The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery. <i>Frontiers in Drug Delivery</i> , 2021, 1, .	0.4	12
16	Formulation strategies to improve the efficacy of intestinal permeation enhancers,. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113925.	6.6	39
17	Measuring the oral bioavailability of protein hydrolysates derived from food sources: A critical review of current bioassays. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112275.	2.5	10
18	Drug Delivery Formulations and Devices Tailored for Paediatric and Older Patients. <i>Frontiers in Drug Delivery</i> , 2021, 1, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Silica-Coated Nanoparticles with a Core of Zinc, <sc>L</sc>-Arginine, and a Peptide Designed for Oral Delivery. ACS Applied Materials & Interfaces, 2020, 12, 1257-1269.	4.0	26
20	Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. European Journal of Pharmaceutical Sciences, 2020, 154, 105509.	1.9	26
21	A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10). European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 95-107.	2.0	39
22	Evolving peptides for oral intake. Nature Biomedical Engineering, 2020, 4, 487-488.	11.6	7
23	Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. Advanced Drug Delivery Reviews, 2020, 157, 2-36.	6.6	150
24	An Enteric-Coated Polyelectrolyte Nanocomplex Delivers Insulin in Rat Intestinal Instillations When Combined with a Permeation Enhancer. Pharmaceutics, 2020, 12, 259.	2.0	18
25	Investigations of Piperazine Derivatives as Intestinal Permeation Enhancers in Isolated Rat Intestinal Tissue Mucosae. AAPS Journal, 2020, 22, 33.	2.2	10
26	Amphiphilic Star Polypept(o)ides as Nanomeric Vectors in Mucosal Drug Delivery. Biomacromolecules, 2020, 21, 2455-2462.	2.6	17
27	Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. Journal of Controlled Release, 2019, 310, 115-126.	4.8	76
28	Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies. Pharmaceutics, 2019, 11, 565.	2.0	32
29	Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update. Pharmaceutics, 2019, 11, 41.	2.0	111
30	Stomaching Drug Delivery. New England Journal of Medicine, 2019, 380, 1671-1673.	13.9	7
31	Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics, 2019, 11, 78.	2.0	141
32	Effect of Overencapsulation on the Disintegration and Dissolution of Licensed Formulations for Blinding in Randomized Controlled Trials. Journal of Pharmaceutical Sciences, 2019, 108, 1227-1235.	1.6	3
33	Labrasol® and Salts of Medium-Chain Fatty Acids Can Be Combined in Low Concentrations to Increase the Permeability of a Macromolecule Marker Across Isolated Rat Intestinal Mucosae. Journal of Pharmaceutical Sciences, 2018, 107, 1648-1655.	1.6	17
34	Effects of surfactant-based permeation enhancers on mannitol permeability, histology, and electrogenic ion transport responses in excised rat colonic mucosae. International Journal of Pharmaceutics, 2018, 539, 11-22.	2.6	35
35	Track analysis of the passage of rhodamine-labeled liposomes across porcine jejunal mucus in a microchannel device. Therapeutic Delivery, 2018, 9, 419-433.	1.2	8
36	Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128, 179-187.	2.0	23

#	ARTICLE	IF	CITATIONS
37	TNF \pm -dependent anhedonia and upregulation of hippocampal serotonin transporter activity in a mouse model of collagen-induced arthritis. <i>Neuropharmacology</i> , 2018, 137, 211-220.	2.0	12
38	The effect of plant sterol-enriched turkey meat on cholesterol bio-accessibility during <i>in vitro</i> digestion and Caco-2 cell uptake. <i>International Journal of Food Sciences and Nutrition</i> , 2018, 69, 176-182.	1.3	6
39	Local delivery of macromolecules to treat diseases associated with the colon. <i>Advanced Drug Delivery Reviews</i> , 2018, 136-137, 2-27.	6.6	72
40	Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1421-1435.	3.0	12
41	Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. <i>Journal of Controlled Release</i> , 2018, 286, 402-414.	4.8	48
42	A human intestinal M-cell-like model for investigating particle, antigen and microorganism translocation. <i>Nature Protocols</i> , 2017, 12, 1387-1399.	5.5	64
43	Evaluation of PepT1 transport of food-derived antihypertensive peptides, Ile-Pro-Pro and Leu-Lys-Pro using <i>in vitro</i> , <i>ex vivo</i> and <i>in vivo</i> transport models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 115, 276-284.	2.0	39
44	Nanoparticle passage through porcine jejunal mucus: Microfluidics and rheology. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 863-873.	1.7	35
45	Progress in the formulation and delivery of somatostatin analogs for acromegaly. <i>Therapeutic Delivery</i> , 2017, 8, 867-878.	1.2	14
46	A comparison of three Peyer's patch M-like cell culture models: particle uptake, bacterial interaction, and epithelial histology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 119, 426-436.	2.0	24
47	Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles. <i>Current Opinion in Pharmacology</i> , 2017, 36, 22-28.	1.7	64
48	Development of a Non-Aqueous Dispersion to Improve Intestinal Epithelial Flux of Poorly Permeable Macromolecules. <i>AAPS Journal</i> , 2017, 19, 244-253.	2.2	6
49	Editorial overview: New technologies: drug delivery and medical devices combinations, more than the sum of the parts. <i>Current Opinion in Pharmacology</i> , 2017, 36, iv-vii.	1.7	0
50	An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers. <i>Pharmaceutical Research</i> , 2016, 33, 2506-2516.	1.7	16
51	Safety concerns over the use of intestinal permeation enhancers: A mini-review. <i>Tissue Barriers</i> , 2016, 4, e1176822.	1.6	101
52	Oral delivery strategies for nutraceuticals: Delivery vehicles and absorption enhancers. <i>Trends in Food Science and Technology</i> , 2016, 53, 90-101.	7.8	93
53	Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. <i>Journal of Controlled Release</i> , 2016, 238, 242-252.	4.8	17
54	Oral delivery of peptides: opportunities and issues for translation. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 193-195.	6.6	50

#	ARTICLE	IF	CITATIONS
55	Introduction for the special issue on recent advances in drug delivery across tissue barriers. <i>Tissue Barriers</i> , 2016, 4, e1187981.	1.6	3
56	Intestinal permeation enhancers for oral peptide delivery. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 277-319.	6.6	266
57	Hepatic gateways. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 561-563.	1.4	0
58	Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 223-241.	6.6	241
59	Stability, toxicity and intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro. <i>Peptides</i> , 2015, 71, 1-7.	1.2	37
60	Development of nanotoxicology: implications for drug delivery and medical devices. <i>Nanomedicine</i> , 2015, 10, 2289-2305.	1.7	11
61	High-content analysis for drug delivery and nanoparticle applications. <i>Drug Discovery Today</i> , 2015, 20, 942-957.	3.2	39
62	In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill [®]) of salmon calcitonin. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 79, 102-111.	1.9	23
63	Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 94, 194-206.	2.0	38
64	First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models. <i>Neuropharmacology</i> , 2015, 89, 193-203.	2.0	18
65	Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 856-865.	2.0	26
66	A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 830-839.	2.0	66
67	Redox-Mediated Angiogenesis in the Hypoxic Joint of Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3300-3310.	2.9	41
68	Progress in the delivery of nanoparticle constructs: towards clinical translation. <i>Current Opinion in Pharmacology</i> , 2014, 18, 120-128.	1.7	43
69	Translocation of <i>Vibrio parahaemolyticus</i> across an in vitro M cell model. <i>FEMS Microbiology Letters</i> , 2014, 350, 65-71.	0.7	11
70	Formulation strategies to improve oral peptide delivery. <i>Pharmaceutical Patent Analyst</i> , 2014, 3, 313-336.	0.4	56
71	Efficacious Intestinal Permeation Enhancement Induced by the Sodium Salt of 10-undecylenic Acid, A Medium Chain Fatty Acid Derivative. <i>AAPS Journal</i> , 2014, 16, 1064-1076.	2.2	28
72	Transepithelial Transport of PAMAM Dendrimers across Isolated Rat Jejunal Mucosae in Ussing Chambers. <i>Biomacromolecules</i> , 2014, 15, 2889-2895.	2.6	14

#	ARTICLE	IF	CITATIONS
73	The role of citric acid in oral peptide and protein formulations: Relationship between calcium chelation and proteolysis inhibition. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 544-551.	2.0	60
74	Poly(Ethylene Glycol)-Based Backbones with High Peptide Loading Capacities. <i>Molecules</i> , 2014, 19, 17559-17577.	1.7	9
75	Human: Veterinary Technology Cross Over. <i>Advances in Delivery Science and Technology</i> , 2013, , 359-375.	0.4	0
76	Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 726-734.	1.9	23
77	An intra-articular salmon calcitonin-based nanocomplex reduces experimental inflammatory arthritis. <i>Journal of Controlled Release</i> , 2013, 167, 120-129.	4.8	60
78	Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. <i>International Journal of Pharmaceutics</i> , 2013, 440, 3-12.	2.6	150
79	Opportunities for drug-delivery research in nutraceuticals and functional foods?. <i>Therapeutic Delivery</i> , 2013, 4, 301-305.	1.2	6
80	Direct Peptide Bioconjugation/PEGylation at Tyrosine with Linear and Branched Polymeric Diazonium Salts. <i>Journal of the American Chemical Society</i> , 2012, 134, 7406-7413.	6.6	122
81	Critical Sorbâ„¢ Promotes Permeation of Flux Markers Across Isolated Rat Intestinal Mucosae and Caco-2 Monolayers. <i>Pharmaceutical Research</i> , 2012, 29, 2543-2554.	1.7	22
82	The mycotoxin patulin increases colonic epithelial permeability in vitro. <i>Food and Chemical Toxicology</i> , 2012, 50, 4097-4102.	1.8	33
83	Evaluation of alkylmaltosides as intestinal permeation enhancers: Comparison between rat intestinal mucosal sheets and Caco-2 monolayers. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 701-712.	1.9	45
84	Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e113-e119.	4.0	74
85	Zinc sulphate attenuates chloride secretion in Human colonic mucosae in vitro. <i>European Journal of Pharmacology</i> , 2012, 696, 166-171.	1.7	14
86	Mechanisms of action of zinc on rat intestinal epithelial electrogenic ion secretion: insights into its antidiarrhoeal actions. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 644-653.	1.2	16
87	Chapter 2.1. Nanostructures Overcoming the Intestinal Barrier: Physiological Considerations and Mechanistic Issues. <i>RSC Drug Discovery Series</i> , 2012, , 39-62.	0.2	4
88	NANOSTRUCTURES OVERCOMING THE INTESTINAL BARRIER: DRUG DELIVERY STRATEGIES. <i>RSC Drug Discovery Series</i> , 2012, , 63-90.	0.2	3
89	Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET [®]). <i>Therapeutic Delivery</i> , 2011, 2, 1595-1610.	1.2	62
90	High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. <i>Peptides</i> , 2011, 32, 1764-1773.	1.2	25

#	ARTICLE	IF	CITATIONS
91	Oral peptide delivery: prioritizing the leading technologies. <i>Therapeutic Delivery</i> , 2011, 2, 1567-1573.	1.2	28
92	PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. <i>Journal of Controlled Release</i> , 2011, 149, 126-132.	4.8	25
93	Chloride-led Disruption of the Intestinal Mucous Layer Impedes <i>Salmonella</i> Invasion: Evidence for an "Enteric Tear" Mechanism. <i>Cellular Physiology and Biochemistry</i> , 2011, 28, 743-752.	1.1	20
94	Resistance of <i>Staphylococcus aureus</i> to the cationic antimicrobial agent poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA). <i>Journal of Medical Microbiology</i> , 2011, 60, 968-976.	0.7	47
95	Restoration of rat colonic epithelium after <i>in situ</i> intestinal instillation of the absorption promoter, sodium caprate. <i>Therapeutic Delivery</i> , 2010, 1, 75-82.	1.2	44
96	High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. <i>Journal of Controlled Release</i> , 2010, 146, 84-92.	4.8	53
97	<i>In vitro</i> and <i>in vivo</i> characterisation of a novel peptide delivery system: Amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes. <i>Journal of Controlled Release</i> , 2010, 147, 289-297.	4.8	38
98	Impact of amino acid replacements on <i>in vitro</i> permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. <i>International Journal of Pharmaceutics</i> , 2010, 387, 154-160.	2.6	27
99	Drug Delivery Systems in Domestic Animal Species. <i>Handbook of Experimental Pharmacology</i> , 2010, , 79-112.	0.9	18
100	Oral absorption enhancement: taking the next steps in therapeutic delivery. <i>Therapeutic Delivery</i> , 2010, 1, 5-9.	1.2	8
101	Antibacterial Effects of Poly(2-(dimethylamino ethyl)methacrylate) against Selected Gram-Positive and Gram-Negative Bacteria. <i>Biomacromolecules</i> , 2010, 11, 443-453.	2.6	208
102	Controlled Release Drug Delivery in Farmed Animals: Commercial Challenges and Academic Opportunities. <i>Current Drug Delivery</i> , 2009, 6, 383-390.	0.8	14
103	Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. <i>Journal of Controlled Release</i> , 2009, 135, 35-43.	4.8	44
104	Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol)) (PPEGMA). <i>Journal of Controlled Release</i> , 2009, 135, 51-59.	4.8	78
105	Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 301-311.	1.9	32
106	Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 291-300.	1.9	46
107	Lymphocyte migration through the blood-brain barrier (BBB) in feline immunodeficiency virus infection is significantly influenced by the pre-existence of virus and tumour necrosis factor (TNF) within the central nervous system (CNS): studies using an <i>in vitro</i> feline BBB model. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 592-602.	1.8	16
108	Site-specific N-terminus conjugation of poly(mPEG1100) methacrylates to salmon calcitonin: synthesis and preliminary biological evaluation. <i>Soft Matter</i> , 2009, 5, 3038.	1.2	26

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 1427-1449.	6.6	195
110	Phosphine-mediated one-pot thiol-ene click approach to polymer-protein conjugates. <i>Chemical Communications</i> , 2009, , 5272.	2.2	110
111	In vitro Interactions Between the Oral Absorption Promoter, Sodium Caprate (C10) and <i>S. typhimurium</i> in Rat Intestinal Ileal Mucosae. <i>Pharmaceutical Research</i> , 2008, 25, 114-122.	1.7	22
112	A Tertiary Amino-Containing Polymethacrylate Polymer Protects Mucus-Covered Intestinal Epithelial Monolayers Against Pathogenic Challenge. <i>Pharmaceutical Research</i> , 2008, 25, 1193-1201.	1.7	16
113	Myosin Light Chain Kinase Inhibition: Correction of Increased Intestinal Epithelial Permeability In Vitro. <i>Pharmaceutical Research</i> , 2008, 25, 1377-1386.	1.7	63
114	Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. <i>Veterinary Research Communications</i> , 2008, 32, 93-106.	0.6	38
115	Effects of <i>Lactobacillus salivarius</i> 433118 on Intestinal Inflammation, Immunity Status and In Vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2495-2506.	1.1	40
116	Advances in PEGylation of important biotech molecules: delivery aspects. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 371-383.	2.4	283
117	Feline immunodeficiency virus infection: A valuable model to study HIV-1 associated encephalitis. <i>Veterinary Immunology and Immunopathology</i> , 2008, 123, 134-137.	0.5	11
118	Increased Intestinal Permeability in Rats Subjected to Traumatic Frontal Lobe Percussion Brain Injury. <i>Journal of Trauma</i> , 2008, 64, 131-138.	2.3	44
119	Cracking the Junction: Update on the Progress of Gastrointestinal Absorption Enhancement in the Delivery of Poorly Absorbed Drugs. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2008, 25, 117-168.	1.2	47
120	Prediction of therapeutic and drug delivery outcomes using animal models. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1071-1072.	6.6	0
121	Melittin as a Permeability Enhancer II: In Vitro Investigations in Human Mucus Secreting Intestinal Monolayers and Rat Colonic Mucosae. <i>Pharmaceutical Research</i> , 2007, 24, 1346-1356.	1.7	31
122	Melittin as an Epithelial Permeability Enhancer I: Investigation of Its Mechanism of Action in Caco-2 Monolayers. <i>Pharmaceutical Research</i> , 2007, 24, 1336-1345.	1.7	35
123	Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET ₂ . <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 685-692.	2.4	108
124	New technologies Pharmacology applied: delivering the goods. <i>Current Opinion in Pharmacology</i> , 2006, 6, 491-493.	1.7	0
125	Growth and characterisation of a cell culture model of the feline blood-brain barrier. <i>Veterinary Immunology and Immunopathology</i> , 2006, 109, 233-244.	0.5	22
126	Fluorescently tagged star polymers by living radical polymerisation for mucoadhesion and bioadhesion. <i>Reactive and Functional Polymers</i> , 2006, 66, 51-64.	2.0	59

#	ARTICLE	IF	CITATIONS
127	Rat, ovine and bovine Peyer's patches mounted in horizontal diffusion chambers display sampling function. <i>Journal of Controlled Release</i> , 2006, 115, 68-77.	4.8	21
128	Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 257-265.	0.6	73
129	Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. <i>Drug Discovery Today</i> , 2005, 10, 1145-1157.	3.2	202
130	Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. <i>Immunology Letters</i> , 2005, 100, 182-188.	1.1	42
131	In Vitro and ex Vivo Intestinal Tissue Models to Measure Mucoadhesion of Poly (Methacrylate) and N-Trimethylated Chitosan Polymers. <i>Pharmaceutical Research</i> , 2005, 22, 38-49.	1.7	89
132	Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. <i>International Immunology</i> , 2004, 16, 91-99.	1.8	77
133	Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. <i>Advanced Drug Delivery Reviews</i> , 2004, 56, 721-726.	6.6	43
134	Oral Delivery of Pathogens from the Intestine to the Nervous System. <i>Journal of Drug Targeting</i> , 2004, 12, 71-78.	2.1	6
135	Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization. <i>Cellular Immunology</i> , 2003, 224, 8-16.	1.4	67
136	In vitro inhibition of cytochalasin induced tight junction opening in human colon. <i>Gastroenterology</i> , 2003, 124, A316.	0.6	0
137	Catching target receptors for drug and vaccine delivery using TOGA [®] gene expression profiling. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1213-1223.	6.6	11
138	Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. <i>Vaccine</i> , 2001, 19, 1940-1950.	1.7	115
139	Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered I ² -amyloid in mice. <i>Vaccine</i> , 2001, 19, 4185-4193.	1.7	22
140	Targeting polymerised liposome vaccine carriers to intestinal M cells. <i>Vaccine</i> , 2001, 20, 208-217.	1.7	117
141	<i>In Vitro</i> Models of the Intestinal Barrier. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 649-668.	0.7	196
142	Microparticle vaccine approaches to stimulate mucosal immunisation. <i>Microbes and Infection</i> , 2001, 3, 867-876.	1.0	62
143	Oral vaccination in man using antigens in particles: current status. <i>European Journal of Pharmaceutical Sciences</i> , 2001, 14, 183-189.	1.9	75
144	Iontophoresis-enhanced absorptive flux of polar molecules across intestinal tissue in vitro. <i>Pharmaceutical Research</i> , 2000, 17, 476-478.	1.7	13

#	ARTICLE	IF	CITATIONS
145	Evaluation of the Caco-2 monolayer as a model epithelium for iontophoretic transport. <i>Pharmaceutical Research</i> , 2000, 17, 1181-1188.	1.7	39
146	Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 808-813.	1.0	246
147	Fast-track approaches to selecting discovery candidates for full development. <i>Drug Discovery Today</i> , 1998, 3, 6-7.	3.2	0
148	Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. <i>European Journal of Pharmaceutical Sciences</i> , 1998, 6, 153-163.	1.9	250
149	Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. <i>Pharmaceutical Science & Technology Today</i> , 1998, 1, 291-299.	0.7	32
150	Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue. <i>Advanced Drug Delivery Reviews</i> , 1997, 23, 111-120.	6.6	47
151	A novel in vitro electrophysiological bioassay for transport of loperamide across intestinal epithelia. <i>Pharmaceutical Research</i> , 1997, 14, 942-945.	1.7	3
152	Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. <i>Pharmaceutical Research</i> , 1997, 14, 1772-1779.	1.7	67
153	Passive transepithelial diltiazem absorption across intestinal tissue leading to tight junction openings. <i>Journal of Controlled Release</i> , 1996, 38, 193-203.	4.8	5
154	Royal academy of medicine in ireland section of biomedical sciences. <i>Irish Journal of Medical Science</i> , 1996, 165, 224-238.	0.8	0
155	Cultured human sweat gland epithelia: isolation of glands using neutral red. <i>Pharmaceutical Research</i> , 1995, 12, 171-175.	1.7	15
156	A distinctive electrophysiological signature from the Peyer's patches of rabbit intestine. <i>British Journal of Pharmacology</i> , 1994, 113, 593-599.	2.7	16
157	Thapsigargin, a new calcium-dependent epithelial anion secretagogue. <i>British Journal of Pharmacology</i> , 1989, 98, 809-816.	2.7	42
158	Human eccrine sweat gland epithelial cultures express ductal characteristics.. <i>Journal of Physiology</i> , 1988, 405, 657-675.	1.3	24
159	Section of biological sciences. <i>Irish Journal of Medical Science</i> , 1986, 155, 125-140.	0.8	1
160	AB069. NR4A1 agonist CsnB may affect macrophage cells primarily within colorectal tumours in order to reduce pro-inflammatory response. <i>Mesentery and Peritoneum</i> , 0, 4, AB069-AB069.	0.1	0
161	AB073. Attenuation of pathogenic pro-inflammatory signals in colorectal cancer via an NR4A1 agonist cytosporone B. <i>Mesentery and Peritoneum</i> , 0, 4, AB073-AB073.	0.1	0